Moderna (MRNA) Revenue & Revenue Breakdown
Moderna Revenue Highlights
Latest Revenue (Y)
$3.24B
Latest Revenue (Q)
$1.85B
Main Segment (Y)
Product Sales
Main Geography (Y)
UNITED STATES
Moderna Revenue by Period
Moderna Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $3.24B | -52.75% |
| 2023-12-31 | $6.85B | -64.45% |
| 2022-12-31 | $19.26B | 8.61% |
| 2021-12-31 | $17.74B | 6361.44% |
| 2020-12-31 | $274.49M | 471.43% |
| 2019-12-31 | $48.04M | -60.79% |
| 2018-12-31 | $122.51M | -30.77% |
| 2017-12-31 | $176.97M | 74.30% |
| 2016-12-31 | $101.54M | - |
Moderna generated $3.24B in revenue during NA 2024, up -52.75% compared to the previous quarter, and up 6736.61% compared to the same period a year ago.
Moderna Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $1.85B | 669.71% |
| 2024-06-30 | $241.00M | 44.31% |
| 2024-03-31 | $167.00M | -94.06% |
| 2023-12-31 | $2.81B | 53.63% |
| 2023-09-30 | $1.83B | 432.27% |
| 2023-06-30 | $344.00M | -81.53% |
| 2023-03-31 | $1.86B | -63.38% |
| 2022-12-31 | $5.08B | 57.89% |
| 2022-09-30 | $3.22B | -29.48% |
| 2022-06-30 | $4.57B | -23.13% |
| 2022-03-31 | $5.94B | -14.52% |
| 2021-12-31 | $6.95B | 43.90% |
| 2021-09-30 | $4.83B | 14.57% |
| 2021-06-30 | $4.21B | 141.82% |
| 2021-03-31 | $1.74B | 659.89% |
| 2020-12-31 | $229.38M | 1777.66% |
| 2020-09-30 | $12.22M | -57.05% |
| 2020-06-30 | $28.44M | 538.14% |
| 2020-03-31 | $4.46M | -57.77% |
| 2019-12-31 | $10.55M | -20.88% |
| 2019-09-30 | $13.34M | 32.98% |
| 2019-06-30 | $10.03M | -28.94% |
| 2019-03-31 | $14.12M | -56.99% |
| 2018-12-31 | $32.82M | -10.49% |
| 2018-09-30 | $36.66M | 41.93% |
| 2018-06-30 | $25.83M | -5.93% |
| 2018-03-31 | $27.46M | -68.94% |
| 2017-12-31 | $88.42M | 108.17% |
| 2017-09-30 | $42.47M | 18.89% |
| 2017-06-30 | $35.72M | - |
| 2017-03-31 | $35.72M | - |
Moderna generated $1.85B in revenue during Q3 2024, up 669.71% compared to the previous quarter, and up 539.24% compared to the same period a year ago.
Moderna Revenue Breakdown
Moderna Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Collaboration Arrangement | $12.00M | $440.00M | $61.00M | - |
| Grant | $37.00M | $388.00M | $735.00M | - |
| Product Sales | $4.52B | $18.43B | $17.68B | - |
| Messenger RNA (mRNA) Medicines | - | $6.85B | - | - |
Moderna's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product Sales (98.93%), Grant (0.81%), and Collaboration Arrangement (0.26%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales | $386.00M | $2.96B | $645.00M | $522.00M | $2.96B | $2.42B | $1.00B | $1.83B | $4.08B | $3.90B | $4.53B | $5.92B | - | $9.62B | $6.14B | $4.47B | - | - | - | - |
| Grant | $9.00M | $8.00M | $20.00M | - | - | $44.00M | $28.00M | $24.00M | - | $144.00M | $183.00M | $126.00M | $262.00M | $140.00M | $139.00M | $194.00M | $341.37M | $145.69M | $37.91M | $3.93M |
| Collaboration Arrangement | - | $7.00M | $6.00M | $3.00M | - | $19.00M | $13.00M | $2.00M | $290.00M | $100.00M | $35.00M | $15.00M | $10.00M | $23.00M | $18.00M | $10.00M | $78.04M | $12.22M | $28.44M | $3.19M |
Moderna's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product Sales (97.72%), and Grant (2.28%).
Moderna Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Europe | $598.00M | $1.35B | $6.82B | $6.85B | - |
| Rest Of The World | $810.00M | $3.60B | $7.30B | $5.45B | $38.87M |
| UNITED STATES | $1.78B | $1.90B | $5.15B | $6.18B | $764.53M |
Moderna's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (55.90%), Rest Of The World (25.37%), and Europe (18.73%).
Quarterly Revenue by Country
| Country | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rest Of The World | $397.00M | $324.00M | $22.00M | $67.00M | $1.38B | $741.00M | $231.00M | $1.25B | $1.61B | $1.09B | $1.69B | $2.90B | - | $3.61B | $2.10B | $375.00M |
| UNITED STATES | $308.00M | $1.22B | $162.00M | $100.00M | $979.00M | $913.00M | $2.00M | $1.00M | $1.77B | $985.00M | $1.45B | $945.00M | $1.53B | $1.20B | $2.09B | $1.36B |
| Europe | $317.00M | $281.00M | - | - | $616.00M | $103.00M | $60.00M | $576.00M | $2.30B | $1.04B | $1.39B | $2.08B | - | - | - | - |
Moderna's latest quarterly revenue breakdown by geography, as of Dec 24: Rest Of The World (38.85%), Europe (31.02%), and UNITED STATES (30.14%).
Moderna Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $11.02B | $2.77B |
| MRNA | Moderna | $3.24B | $1.85B |
| NVAX | Novavax | $682.16M | $415.48M |
| KRYS | Krystal Biotech | $290.51M | $83.84M |
| DNA | Ginkgo Bioworks | $227.04M | $89.05M |
| CVAC | CureVac | $52.70M | $12.37M |
| OCEA | Ocean Biomedical | - | - |
| NTLA | Intellia Therapeutics | - | $9.11M |
| EDIT | Editas Medicine | - | - |
| RAIN | Rain Enhancement Technologies Holdco | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| ELEV | Elevation Oncology | - | - |
| ENVB | Enveric Biosciences | - | - |
| BEAM | Beam Therapeutics | - | $14.27M |